Ascentage to commence U.S. trials of HQP1351 in TKI resistant leukemia
Category: #health  By Mateen Dalal  Date: 2019-07-23
  • share
  • Twitter
  • Facebook
  • LinkedIn

Ascentage to commence U.S. trials of HQP1351 in TKI resistant leukemia

The Phase 1b clinical trial can accelerate HQP1351’s clinical development program globally

Ascentage Pharma, a biotechnology company that is involved in the development of novel therapies for hepatitis B virus, age-related diseases and cancers, recently announced that the Food & Drug Administration (FDA) has cleared an Investigational New drug (IND) application that enables the company to initiate a Phase 1b clinical trial of HQP1351 in the U.S.

For the record, HQP1351 is a drug candidate that Ascentage Pharma has developed to treat patients with tyrosine kinase inhibitors (TKI)- resistant chronic myeloid leukemia (CML).

Apparently, HQP1351 happens to be Ascentage’s sixth molecule that received IND clearance from FDA. The company had reportedly submitted data to FDA which was generated from more than 100 subjects in Phase 1 trial in China in order to support the applications for IND.

According to reports, the clinical study is Phase Ib clinical trial that gives three dose cohorts that is more efficient compared to the traditional 3+3 dose-escalation study and could accelerate the clinical trial’s progress. The trial is designed to evaluate tolerability, pharmacokinetic and safety of HQP1351 in patients who are suffering from CML and are intolerant and resistant to the second-line TKIs, as well as to confirm the Phase II dose (RP2D) as recommended.

Seemingly, at the 60th American Society of Hematology (ASH) Annual Meeting, data from HQP1351 Phase 1 study in China had been accepted as an oral presentation last December. HQP13351 had been effective while treating the first and the second generation TKI-resistant CML, more importantly the highly resistant CML with T3151 mutations, along with enhanced safety profile in comparison with the other agents in the same class.

The results demonstrated best-in-class potential of HQP1351 for the treatment of TKI-resistant CML.

Ascentage Pharma’s Chief Medical Officer, Dr. Yifan Zhai stated that the Phase 1b clinical trial can accelerate HQP1351’s clinical development program significantly. The company hopes for HQP1351 to meet patients’ unmet clinical need worldwide.

Source Credits-

https://www.prnewswire.com/news-releases/ascentage-pharma-to-initiate-phase-ib-study-of-hqp1351-in-tyrosine-kinase-inhibitors--resistant-chronic-myeloid-leukemia-patients-in-the-us-300888373.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Ather Energy raises $250 million to stay ahead in competition
Ather Energy raises $250 million to stay ahead in competition
By Mateen Dalal

Electric scooter producer Ather Energy has reportedly secured $250 million in a new funding round. As per reports, the investment round is in its early stages. The company’s goal is to obtain $200 million to $250 million to compete in the EV...

Digital wellness startup Mojorcare bags USD 20 Mn in Series A funding
Digital wellness startup Mojorcare bags USD 20 Mn in Series A funding
By Mateen Dalal

Mojocare, a wellness and health startup has reportedly raised USD 20.6 million in a Series A round of funding which was led by B Capital Group and saw participation from existing investors including Sequoia India’s Surge, Better Capital, and Ch...

Exponent Energy bags USD 13 million in Lightspeed-led Series A funding
Exponent Energy bags USD 13 million in Lightspeed-led Series A funding
By Mateen Dalal

Bangalore-based Exponent Energy has reportedly secured USD 13 million in a Series A funding round which was spearheaded by Lightspeed Venture Partners. The round also saw participation from existing investors such as 3one4 Capital, YourNest VC, and A...